April K.S. Salama

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Life Sciences, Immunology, Oncology +17

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.6K citations · Full text

Medicine, Clinical Sciences, Oncology +15

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi, Jason Chesney, Anna C. Pavlick et al. · The Lancet Oncology · 2016 · 980 citations

Medicine, Immunology, Oncology +17

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Paul Nathan, Jessica C. Hassel, Piotr Rutkowski et al. · New England Journal of Medicine · 2021 · 878 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Daniel G. Coit, John A. Thompson, Mark R. Albertini et al. · Journal of the National Comprehensive Cancer Network · 2019 · 438 citations · Full text

Medicine, Dermatology, Oncology +17